OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Indeterminate pulmonary nodules in non‐rhabdomyosarcoma soft tissue sarcoma: A study of the European paediatric Soft Tissue Sarcoma Study Group	1484
Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivors	309
Issue Information	221
A local perspective on internal, external, and reflexive biomarker testing processes for lung cancer in an academic medical center	175
Modeled residual current cancer risk after clinical investigation of a positive multicancer early detection test result	153
Impact of TAILORx on chemotherapy prescribing and 21‐gene recurrence score–guided treatment costs in a population‐based cohort of patients with breast cancer	145
Measuring the impact of a catchment area surveillance tool on cancer center adopters	132
Impact of obesity on outcome in children diagnosed with cancer in Canada: A report from Cancer in Young People in Canada	118
	112
Dietary supplement use among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study	110
First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors	104
Effect of a 1‐year physical activity intervention on quality of life, fatigue, and distress in adult childhood cancer survivors—A randomized controlled trial (SURfit)	104
Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532	97
Adjuvant cyclin‐dependent kinase 4/6 inhibition in hormone receptor–positive breast cancer: One Monarch to rule them all?	93
Association of statin use with clinical outcomes in patients with triple‐negative breast cancer	88
Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019	88
Individual‐ and neighborhood‐level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California	85
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study	72
Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery	70
Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan	68
Risk model‐based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model	66
Risk of suicide among individuals with a history of childhood cancer	55
Oncology patients' perception of physicians who use an integrated electronic health record (EHR) during clinic visits: PRIME‐EHR double‐blind, randomized controlled trial	54
Reply to “Empathic communication: The premise of inclusive care for historically excluded populations”	53
Intersecting identities and cancer screening	52

Issue Information	51
More social determinants lead to more cancer death: A tragic dose response	49
Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study	49
Lower risk of depression after smoking cessation and alcohol abstinence in patients with gastric cancer who underwent gastrectomy: A population‐based, nationwide cohort study	49
Pediatric inflammatory bowel disease increases cancer risk	49
Issue Information	49
New standard of care for multiple myeloma?	48
Altering the microbiome for immunotherapy‐resistant urological tumors—An intriguing but still early concept	48
MRI‐guided radiotherapy results in fewer toxicities for localized prostate cancer	47
First person profile: Mary‐Ellen Taplin, MD	47
Issue Information	47
Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?	46
Talazoparib for newly diagnosed prostate cancer associated with significant risk reduction of disease progression	46
Frequency and clinical associations of common mental disorders in adults with high‐grade glioma—A multicenter study	45
Feasibility of structuring electronic health record data to facilitate real‐world data research: ICAREdata methods applied to multicenter cancer clinical trials	45
Withdrawal: “Assessment of prognostic understanding, perceived goals of care, and quality of life in hospitalized patients with leukemia or multiple myeloma” Olivia S. Allen, Nina Kim, Jose Morillo, C	45
Risk scores predicting disease progression in early‐stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy	42
Federal Cervical Cancer Collaborative: Improving cervical cancer prevention through vaccination, screening, and management in safety‐net settings of care	42
Improved survival and decreased cancer deaths in young adults with cancer after passage of the Affordable Care Act Dependent Coverage Expansion	42
Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta‐analysis	42
Agreement of medical record abstraction and self‐report of breast cancer treatment with an extended recall window	42
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial	42